Ocular Therapeutix Inc’s filing revealed that its Chief Medical Officer Waheed Nadia unloaded Company’s shares for reported $0.11 million on Jun 02 ’25. In the deal valued at $8.05 per share,13,861 shares were sold. As a result of this transaction, Waheed Nadia now holds 206,805 shares worth roughly $1.72 million.
Then, NADIA K. WAHEED bought 13,861 shares, generating $111,524 in total proceeds.
Before that, Nayak Sanjay sold 1,862 shares. Ocular Therapeutix Inc shares valued at $13,351 were divested by the Chief Strategy Officer at a price of $7.17 per share. As a result of the transaction, Nayak Sanjay now holds 281,623 shares, worth roughly $2.34 million.
William Blair initiated its Ocular Therapeutix Inc [OCUL] rating to an Outperform in a research note published recently. A number of analysts have revised their coverage, including RBC Capital Mkts’s analysts, who began to cover the stock in mid March with a ‘”an Outperform”‘ rating. Needham began covering OCUL with “Buy” recommendation on March 11, 2025. Scotiabank started covering the stock on October 16, 2024. It rated OCUL as “a Sector outperform”.
Price Performance Review of OCUL
On Tuesday, Ocular Therapeutix Inc [NASDAQ:OCUL] saw its stock fall -5.14% to $8.30. Over the last five days, the stock has lost -6.85%. Ocular Therapeutix Inc shares have fallen nearly -2.81% since the year began. Nevertheless, the stocks have risen 64.68% over the past one year. While a 52-week high of $11.77 was reached on 06/10/25, a 52-week low of $5.34 was recorded on 03/04/25.
Levels Of Support And Resistance For OCUL Stock
The 24-hour chart illustrates a support level at 8.10, which if violated will result in even more drops to 7.91. On the upside, there is a resistance level at 8.65. A further resistance level may holdings at 9.01.
